App-Quantinova.ai

Anti-B7-H3 antibody-drug conjugates as potential therapeutics for solid cancer

Deryk Loo - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Combination effect of afatinib and BI836845, a humanized IGF ligand-neutralizing antibody, on EGFR-TKI-resistant NSCLC cells

Tohru Ohmori - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Figitumumab

Preclinical pharmacology and repeated dose toxicity of the novel agonistic TWEAK receptor binding antibody BAY-356

Sandra Berndt - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Killing cancer one cell at a time: Development and characterization of a novel antibody drug conjugate

Michael Xiao - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cysteine Hydrochloride

Utilization of podoplanin as a chemotherapeutic target for oral squamous cell carcinoma

Edward P. Retzbach - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Assays for the selection and functional characterization of antibody-drug conjugates at the National Research Council of Canada

Maria L. Jaramillo - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

monomethyl auristatin E

A novel synergistic antibody pair targeting non-overlapping epitopes of MET effectively inhibits MET-driven cancer models

Michael M. Grandal - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

L-Tyrosine

Fluorinated N, N-diarylureas treatment as effective strategy to target colorectal cancer stem cells

Piotr Rychahou - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Metformin Hydrochloride

Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials

Stephane Ferretti - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

HDM 201

NVP-HDM201: cellular and in vivo profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2

Sebastien Jeay - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

HDM 201

Highly specific ATR inhibitors as a therapeutic approach for a broad spectrum of cancers

Laura R. Butler - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

New small molecules targeting MYC:MAX interactions that inhibits tumor cell growth in a MYC-dependent manner

Alina Castell - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

folitixorin calcium

Indolo-pyrido-isoquinolin based alkaloid inhibits epithelial-mesenchymal transition and stemness via activation of p53-miR34a axis

Arumugam Nagalingam - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

BGB-283: a novel RAF Dimer inhibitor, displays potent antitumor activity in HCC patient derived xenograft models

Zhiyu Tang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Sorafenib

ONC201 sensitivity profiling indicates pronounced sensitivity in lymphoid, prostate, colon and brain tumors

Rohinton Tarapore - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TIC 10

Anti-cancer activity of a stable, orally active angiotensin-(1-7) analog

Patricia E. Gallagher - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Angiotensin II

A novel Ras inhibitor potently and selectively suppresses lung tumor cell growth by blocking Ras-Raf binding

Bing Zhu - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

NVP-HDM201: Biochemical and biophysical profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2

Therese Stachyra-Valat - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

HDM 201

Targeting epigenetic regulation in clear cell renal cell carcinoma

Anthony J. Apostoli - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A novel microtubule-disrupting indole-based chalcone that induces caspase-independent cell death in glioblastoma and melanoma cells

Shengnan Du - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Vinblastine

Filters

41730 Abstracts